GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Shiller PE Ratio

Cadence Pharmaceuticals, (FRA:QEW) Shiller PE Ratio : (As of Jun. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cadence Pharmaceuticals, Shiller PE Ratio Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Shiller PE Ratio Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cadence Pharmaceuticals,'s Shiller PE Ratio

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadence Pharmaceuticals,'s Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Shiller PE Ratio falls into.



Cadence Pharmaceuticals, Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cadence Pharmaceuticals,'s E10 for the fiscal year that ended in Dec13 is calculated as:

For example, Cadence Pharmaceuticals,'s adjusted earnings per share data for the fiscal year that ended in Dec13 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec13 (Change)*Current CPI (Dec13)
=-0.204/98.3259*98.3259
=-0.204

Current CPI (Dec13) = 98.3259.

Cadence Pharmaceuticals, Annual Data

Earnings per Share (Diluted) CPI Adj_EPS
200412 -2.313 80.290 -2.833
200512 -5.623 83.032 -6.659
200612 -7.623 85.142 -8.803
200712 -1.243 88.616 -1.379
200812 -1.147 88.697 -1.272
200912 -0.638 91.111 -0.689
201012 -0.824 92.474 -0.876
201112 -1.072 95.213 -1.107
201212 -0.724 96.871 -0.735
201312 -0.204 98.326 -0.204

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cadence Pharmaceuticals,  (FRA:QEW) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cadence Pharmaceuticals, Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines